B2i Digital Featured Company_Kiora Pharmaceuticals Inc_Nasdaq KPRX_Logo White
Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals (Nasdaq: KPRX) develops new medicines to help people with eye diseases see better. Their goal is to improve vision and eye health for patients.

Kiora's name comes from a Maori phrase meaning "have life" or "be healthy." The company name reflects its mission to help give the gift of better vision and eye health to more people.

With a refreshed leadership team and a revolutionary small molecule, KIO-301, Kiora Pharmaceuticals aims to make a positive difference for patients struggling with vision problems.

Nasdaq: KPRX
IR Website: https://ir.kiorapharma.com
Nasdaq Profile: https://www.nasdaq.com/market-activity/stocks/kprx
Headquarters: Encinitas, California

Kiora Pharmaceuticals emerged in November 2021 as part of a major strategic shift in its clinical development strategy under the direction of its new CEO, Brian Strem, Ph.D., and the acquisition of Bayon Therapeutics, the company he co-founded with Kiora’s Chief Development Officer, Eric Daniels, M.D., to develop KIO-301. Today, the company is focused on the treatment of rare vision disorders caused by damage to the retina. KIO-301, its priority pipeline asset, is a molecular photoswitch designed to restore light perception in patients with inherited or age-related retinal degeneration like Retinitis Pigmentosa. Kiora initiated a Phase 1b trial of KIO-301 in late 2022, with full results expected in Q4 2023. Based on early-reported findings, the Company expanded development to Choroideremia and Stargardt’s Disease, two additional inherited retinal diseases that could be addressed with a molecular photoswitch. If successful, the company believes KIO-301 could offer patients with certain rare eye diseases a revolutionary treatment option.

TALK TO MANAGEMENT

Kiora Pharmaceuticals is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.

All content on this page is accurate as of 11.18.23.

Kiora Pharmaceuticals At A Glance

Press Releases & Media Coverage

Investor Presentation

Stock Chart (Intraday)

Stock Chart (Historical)

Stock Detail

A Video Overview of Kiora Pharmaceuticals

Kiora Pharmaceuticals Focuses on Treatments for Rare Blinding Conditions

KIO-301 Is a Potential Vision-Restoring Medicine for Certain Incurable Eye Diseases

KIO-301 Uses a Novel Mechanism

Orphan Drug Designation From The FDA

Phase 1b Safety Data and Evidence of Biological Activity

KIO-104: A Fresh Approach to Uveitis Management

KIO-104: Phase 1 Study Design

Financings and Capitalization

Robust IP and Patent Protection

Pipeline and Upcoming Milestones

An Experienced and Proven Management Team

Strategically Located in San Diego Biotech Hub

SEC Filings

Financials

Risks & Disclosures

B2i Digital Featured Company_Kiora Pharmaceuticals Inc_Nasdaq KPRX_Logo White

The Kiora Pharmaceuticals management and investor relations team are available to talk to current and potential investors. They're happy to answer your questions and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.

• Directly hear the Kiora Pharmaceuticals story
• Ask your questions
• Submit the form below, and someone will get in touch with you as soon as possible

Note: Company management or its representative can only discuss and disclose information that is already available in the public domain. They will do their best to clarify such information to the extent permitted by securities law and industry regulations.